The importance of circulating tumor cells (CTCs) in cancer research is broadly accepted in the scientific community today. Since CTCs undergo phenotypic changes known as the epithelial-to-mesenchymal transition (EMT), they are a valuable indicator for disease progression and therapy resistance. To learn from CTCs, we must be able to effectively detect and characterize them. There… Read article →
Kjell Kirschbaum, M.Sc., is a Global Market Manager based in QIAGEN’s Venlo office, the Netherlands. He trained as a bioveterinary scientist at the University of Utrecht and has hands-on experience in nucleic acid and protein purification, cell culture, PCR and qPCR technology. Kjell joined QIAGEN in 2011 as a CRM specialist, regularly interacting with customers about their day-to-day experimental needs and offering relevant solutions. Currently, he is involved in managing global projects for sample preparation and automation technologies.